Mink Therapeutics, INC

MiNK Therapeutics announced second quarter 2026 financial results and provided positive initial observations from its Phase 2 trial of agenT-797 in acute lung injury, alongside establishing a paid international named-patient access program.

MiNK Therapeutics announced first quarter 2026 financial results, highlighting the initiation of a Phase 2 trial for agenT-797 in acute lung injury and advancements in its iNKT cell therapy platform.

MiNK Therapeutics reported Q4 and full-year 2025 financial results, highlighting advancements in its Phase 2 programs for ARDS and GVHD, bolstered by significant non-dilutive funding.

MiNK Therapeutics addresses investor inquiries, confirming active discussions for agenT-797 combination trials and strategic investments.

MiNK Therapeutics announced the appointment of Melissa Orilall as Principal Financial Officer and Austin Charette as Principal Accounting Officer, effective March 13, 2026.

Dr. Robert Kadlec has resigned from MiNK Therapeutics' Board of Directors to accept a senior public service position within the U.S. government.

MiNK Therapeutics reported an increased net loss for Q3 2025, while highlighting promising clinical progress for its iNKT cell therapies and securing significant equity financing.

MiNK Therapeutics reported increased net losses and a significant cash burn, raising substantial doubt about its ability to continue as a going concern, despite advancing its iNKT cell therapy pipeline.

MiNK Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to liquidity challenges, despite ongoing clinical development and pipeline advancements.

MiNK Therapeutics reported its third quarter 2024 financial results, highlighting a decrease in operating expenses and advancements in its iNKT cell therapy programs.

MiNK Therapeutics reports a net loss of $6.5 million for the first six months of 2024, while highlighting progress in clinical trials and strategic collaborations.

MiNK Therapeutics reported a net loss of $3.8 million for the first quarter of 2024, while highlighting progress in its clinical programs and securing additional funding.

MiNK Therapeutics reported increased net losses and a going concern warning in its 2025 annual report, while highlighting promising clinical progress for its lead iNKT cell therapy, agenT-797, in oncology and pulmonary diseases.

MiNK Therapeutics details its 2024 financial results and provides an update on its clinical development programs, including agenT-797 and engineered iNKT cell therapies, along with strategic collaborations aimed at advancing cancer treatments.

MiNK Therapeutics has obtained a convertible promissory note of up to $5 million from Agenus, while also filing its annual 10-K report detailing its financial status and clinical progress.

Ulf Wiinberg, a Director of MiNK Therapeutics, Inc., received 1,279 shares of common stock on September 1, 2026.

John Bradley Holcomb, a Director of MiNK Therapeutics, Inc., received 1,233 shares of common stock on September 1, 2026.

Peter Behner, a Director of MiNK Therapeutics, Inc., received 1,485 shares of common stock on September 1, 2026.

Barbara Ryan, a Director of MiNK Therapeutics, Inc., received 1,622 shares of common stock on September 1, 2026.

Brian Corvese, a Director of MiNK Therapeutics, Inc., received 1,633 shares of common stock on September 1, 2026.

Director Barbara Ryan sold 1,500 shares of MiNK Therapeutics, Inc. common stock on June 4, 2026.

MiNK Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 17, 2026.

MiNK Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, featuring proposals including director elections, an option exchange, and ratification of the company's accounting firm.

MiNK Therapeutics is seeking stockholder approval for a 1-for-10 reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement.

MiNK Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, featuring proposals for director elections and auditor ratification.